Protea Biosciences Group competitors

With a proven track record of bringing game-changing technologies to the market, Mr. Shamir joined Luminex Corporation as President, Chief Executive Officer, and Board Member in 2014. From 2006 to 2014, Mr. Shamir served as President and CEO of Given Imaging, a developer, manufacturer, and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, which was acquired by Covidien PLC in early 2014. Mr. Shamir currently serves on the board of directors of Exalenz Bioscience Ltd. (TASE: EXEN). He has previously served as a Board Member at Scitex Corporation, Cogentix Medical (NASDAQ: CGNT), recently acquired by Laborie Medical Technologies, and invendo medical GmBH, now part of Ambu. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

Dr. Singh was elected President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined PerkinElmer as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining PerkinElmer, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent six years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.

Vijay Samant is a Board Member at Brickell Biotech Inc. He has worked as President/CEO at Vical; Trustee at International Vaccine Institute (IVI); and VP:Vaccine/Exec Dir:Materials Mgmt at MERCK & CO., INC.. Vijay studied at Columbia University, University of Mumbai, and MIT Sloan.

David Andrew Fischel (born 1 April 1958) is a British businessman. He was formerly the chief executive of Intu Properties Group plc, a British shopping centre management and development company between 2001 and 2019.